Toni K. Choueiri

This study identifies fusion-driven oncogenic programs in translocation renal cell carcinoma (tRCC) that shape an immunosuppressive tumor microenvironment, explaining its reduced immunotherapy response.

The paper identifies DPP9 as a genetic susceptibility gene for checkpoint inhibitor pneumonitis and shows IL-18 blockade could be a therapeutic strategy.

This study identifies epigenetic subtypes of high-grade T1 bladder cancer using integrated chromatin and transcriptomic data, revealing intra-tumor heterogeneity and distinct tumor microenvironment interactions.

This study investigates how transcription factor subtypes in small cell lung cancer influence response and resistance to DLL3-targeted therapy, revealing subtype-specific mechanisms of resistance.

SpatialFusion identifies spatial niches through pathway activation patterns, revealing pre-malignant and malignant microenvironments in cancer tissues.

The paper identifies an IFN response-high epigenetic program linked to BAP1 deficiency in kidney cancer using single nucleus ATAC sequencing across multiple cohorts.

APEX infers cancer gene expression from plasma cfChIP-seq data, outperforming existing methods and enabling subtype classification and biomarker identification.

This paper detects and monitors translocation renal cell carcinoma (tRCC) using plasma cell-free epigenomic profiling, achieving high accuracy in distinguishing tRCC from other cancers and healthy controls.

This study identifies HIF2-driven PTHrP as a cause of cachexia and hypercalcemia in kidney cancer and shows that HIF2 inhibitors can alleviate these symptoms.

This study identifies CDK4/6 and mTORC1 pathway activation in tRCC and shows that their dual inhibition synergistically suppresses tRCC cell growth in vitro and xenografts in vivo.

The paper identifies immune spatial organization as a biomarker predicting metastasis risk in high-grade prostate cancer using computational pathology and H&E slides.

This study identifies TFE3 fusions driving OXPHOS in tRCC and reveals EGLN1 inhibition as a therapeutic target.

This study uses machine learning to infer gene dependencies from tumor transcriptomes, identifying cancer vulnerabilities in rare cancers without experimental screening.

The paper identifies epigenomic signatures in sarcomatoid renal cell carcinoma (sRCC) that predict response to immune checkpoint inhibitors and are detectable in plasma, enabling non-invasive diagnosis.

This study identifies germline rare variants associated with clear and non-clear cell RCC, accounting for population stratification, and finds distinct risk patterns and somatic associations.

This study identifies three germline variants associated with immune-related adverse events in patients treated with immune checkpoint inhibitors.

The paper identifies allele-specific quantitative trait loci (asQTLs) in RCC, showing their enrichment in GWAS risk loci and linking them to hypoxia pathway interactions.

This paper identifies a vulnerability in clear-cell renal cell carcinoma cells to ferroptosis induced by GPX4 inhibition, driven by the HIF-2-HILPDA pathway and PUFA-lipid enrichment.